特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
229758

放射線毒性 (放射能障害・急性放射線症候群) :パイプライン製品の分析

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 278 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
放射線毒性 (放射能障害・急性放射線症候群) :パイプライン製品の分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 278 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射線毒性 (放射能障害・急性放射線症候群) は、非常に短い期間に (通常はわずか数分で) 高線量の放射線が全身 (またはほぼ全身) を透過することで引き起こされる急性疾患です。主な原因は、特異組織の未成熟な実質性幹細胞の減少です。鼻・口・歯茎からの出血、血便、あざ、精神錯乱、脱水、下痢、失神、疲労などの症状が見られます。

当レポートでは、放射線毒性 (放射能障害・急性放射線症候群) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

放射線毒性 (放射能障害・急性放射線症候群) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

放射線毒性 (放射能障害・急性放射線症候群) :企業で開発中の治療薬

放射線毒性 (放射能障害・急性放射線症候群) :大学/機関で研究中の治療薬

放射線毒性 (放射能障害・急性放射線症候群) :パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

放射線毒性 (放射能障害・急性放射線症候群) :企業で開発中の製品

放射線毒性 (放射能障害・急性放射線症候群) :大学/機関で研究中の製品

放射線毒性 (放射能障害・急性放射線症候群) の治療薬開発に従事している企業

  • Aeolus Pharmaceuticals, Inc.
  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Avaxia Biologics, Inc.
  • Bolder Biotechnology, Inc.
  • Caladrius Biosciences, Inc.
  • Cellerant Therapeutics, Inc.
  • Cellphire, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Cleveland BioLabs, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Diffusion Pharmaceuticals Inc.
  • Eli Lilly and Company
  • GNI Group Ltd.
  • Humanetics Corporation
  • INSYS Therapeutics, Inc.
  • Meabco A/S
  • Neumedicines Inc.
  • Onconova Therapeutics, Inc.
  • PharmaIN Corporation
  • Pluristem Therapeutics Inc.
  • ProCertus BioPharm Inc.
  • RDD Pharma Ltd.
  • RedHill Biopharma Ltd.
  • RxBio, Inc.
  • Soligenix, Inc.
  • Stemedica Cell Technologies, Inc.
  • Terapio Corporation
  • Tonix Pharmaceuticals Holding Corp.

放射線毒性 (放射能障害・急性放射線症候群) :治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

放射線毒性 (放射能障害・急性放射線症候群) :最近のパイプライン動向

放射線毒性 (放射能障害・急性放射線症候群) :休止中のプロジェクト

放射線毒性 (放射能障害・急性放射線症候群) :開発が中止された製品

放射線毒性 (放射能障害・急性放射線症候群) :製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by 21st Century Therapeutics Inc, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Advanced Innovative Partners Inc, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Advenchen Laboratories LLC, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Amryt Pharma Plc, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12111IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2020, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 7, 8, 1, 44, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiation Toxicity (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Toxicology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.